Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. - Wikidata - awgldk - TriplyDB

Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.

Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.

http://www.wikidata.org/entity/Q34552576

about

Extracellular Matrix, a Hard Player in Angiogenesis Synergistic antitumor effects of endostar in combination with oxaliplatin via inhibition of HIF and CXCR4 in the colorectal cell line SW1116 Glioma angiogenesis: Towards novel RNA therapeutics.Chondromodulin-1 directly suppresses growth of human cancer cells Molecular mediators of angiogenesis.Shedding of distinct cryptic collagen epitope (HU177) in sera of melanoma patients Multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer.Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV.Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies Tamoxifen and flaxseed alter angiogenesis regulators in normal human breast tissue in vivo.Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer Anti-tumor effect of a novel soluble recombinant human endostatin: administered as a single agent or in combination with chemotherapy agents in mouse tumor models.The potential of nanomedicine therapies to treat neovascular disease in the retina.Gene therapy in pancreatic cancer.From antiangiogenesis to hypoxia: current research and future directions.Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase.Engineering endostatin-producing cartilaginous constructs for cartilage repair using nonviral transfection of chondrocyte-seeded and mesenchymal-stem-cell-seeded collagen scaffolds.Targeted therapy in advanced well-differentiated neuroendocrine tumors.Extension of the in vivo half-life of endostatin and its improved anti-tumor activities upon fusion to a humanized antibody against tumor-associated glycoprotein 72 in a mouse model of human colorectal carcinoma.Deciphering the anti-angiogenic effect of endostatin/cyclophosphamide to normalize tumor micrangium through notch signaling pathway in colon cancer.Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer.Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition.Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications.Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy.Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.Angiogenesis inhibitors and the need for anti-angiogenic therapeutics.Biology and treatment of metastatic gastrointestinal neuroendocrine tumors.Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib Role of radiotherapy for pancreatobiliary neuroendocrine tumors.Tumoristatic effects of endostatin in prostate cancer is dependent on androgen receptor status.A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.Tumor angiogenesis: insights and innovations.Tumor vasculature as target for therapeutic intervention.Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors.Translation of molecular pathways into clinical trials of neuroendocrine tumors.Antiangiogenic and anticancer molecules in cartilage.

P2860

Q28072886-99391D03-06D5-489C-BCFD-1C3E29EB710A Q28484315-14C4CFAC-66E0-4DFB-88C5-A81E09376832 Q33414996-5F58861E-6BF2-40C5-8C59-61A6928624A0 Q33456250-89574017-69BF-49BC-B00A-B42F9DD93D11 Q33639474-977458DC-B6D3-40BB-8FBC-FDFB05CD4F97 Q33673592-6CA4BF91-CFB7-4AFA-BCC2-034079A4C32B Q33724272-3F81A50B-DE45-4742-ADA2-A5649A42FD8B Q33733758-69F939A1-EA75-4407-A62B-B197C52B8858 Q33829625-0489C1F9-2C5A-4EE4-840E-1723E834944A Q33840177-70D850BA-04D8-44B3-9830-924FA84D2270 Q34044998-59FEDEE6-1FD6-40D1-85F9-8C58EFF74908 Q34128953-148A098B-6A39-43CD-AFF3-08CC86193D57 Q34208826-E5670233-418B-44DE-94F1-537B304B0BD7 Q34220590-F6DE97EE-43B7-450B-BC26-92C88676AD77 Q34302954-6E062946-4C29-4E9B-BECC-E6CD65B58186 Q34621100-D1A9DA2F-4917-4E71-8258-7C5C39F8306E Q35124738-8C8A31F8-E381-4C8E-A7E5-76559E4B5E36 Q35161745-FACCAC55-D28D-4E78-8C43-574469D5955C Q35290727-A57B02B4-6006-4535-80DD-17A4582E5028 Q35584497-4BC5CCB8-9498-4AED-93B5-0138F8D4A6A2 Q35740177-30E2D571-9634-4FE5-9E25-F7C80F29E977 Q35893143-C5CEA402-B0ED-4924-8487-F31B63266546 Q36050039-90183645-5204-4216-9E2D-089ECA073B9D Q36094099-02E5B0C2-8E9C-4FF9-998C-A53C9DA5884E Q36220259-756E7C03-6949-4C37-82D0-7924F22B720D Q36578668-FD8B2757-74A9-48BF-9894-C15127B19D84 Q36790050-1CF913E9-239A-4266-AFF5-896B104BC5DE Q36881812-59A5E730-FC34-438D-A68C-B072AABF88DC Q36892294-51036EB8-7222-4C49-86BE-09DF8D5323C5 Q36949560-148B21E2-3CCD-422E-9F39-367F445958A8 Q37077832-DB7B3C0D-DABE-4D4D-A45B-EA37B6B91AFD Q37130616-EC65983D-1FAD-4AA3-82E5-1DC07931952E Q37231180-2E66F269-271C-4D50-8E24-6C6A13394483 Q37380366-4BFC8374-DF1F-4FCD-B3BE-D7290394191D Q37640526-3C7EB455-E57E-439E-9B61-BB2764DA91A9 Q37743207-4030D262-D5BC-4BE5-84FF-566A61F79560 Q37800110-BEE031B5-E33C-4B33-A27D-F2EB9ED4D866 Q37936908-8F6A6ED0-B19C-4B7B-A111-5EE2A7BC0867 Q38003074-208D0C28-45F3-4674-BE4B-A8A8F5754BFC Q38007565-3BFDC591-92B8-4CC8-BD09-A194C1213607

P2860

Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.

http://www.wikidata.org/entity/Q34552576

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Phase II study of recombinant ...... dvanced neuroendocrine tumors.

@ast

Phase II study of recombinant ...... dvanced neuroendocrine tumors.

@en

Phase II study of recombinant ...... dvanced neuroendocrine tumors.

@nl

type

label

Phase II study of recombinant ...... dvanced neuroendocrine tumors.

@ast

Phase II study of recombinant ...... dvanced neuroendocrine tumors.

@en

Phase II study of recombinant ...... dvanced neuroendocrine tumors.

@nl

prefLabel

Phase II study of recombinant ...... dvanced neuroendocrine tumors.

@ast

Phase II study of recombinant ...... dvanced neuroendocrine tumors.

@en

Phase II study of recombinant ...... dvanced neuroendocrine tumors.

@nl

P1433

Q34552576-883274C4-9E2F-4C53-A13C-20EA817F9657

P1476

Q34552576-97FCD360-C009-46B0-A8B8-4F4F52CA505C

P2093

Q34552576-0BABCFAF-FD5D-4271-BA45-52243A6EF8A5

Q34552576-0BE1F9F3-78FE-4DBB-8A8E-A87CE3B596D8

Q34552576-13AAA3A4-BB2C-4F9D-978A-D2E452D5B212

Q34552576-3A028B00-74BA-4E49-8BB2-8549E14536A1

Q34552576-3B500371-7A8E-40B8-A0A2-7B019F0260DC

Q34552576-3D56D83D-C0EE-40B3-985A-2B2ABC43123B

Q34552576-5342C134-21B2-4D68-B129-47BCC7159B7F

Q34552576-8B4C3D0A-F93C-45A5-AEA9-FBEF63E68FB7

Q34552576-A8DEADD8-D674-4C6C-95A0-AEBBC3A846BF

Q34552576-E0A6AD36-431A-489E-98FE-7733D4576895

P304

Q34552576-153BB3C3-A49D-4482-92E8-AEFE72862C89

P31

Q34552576-AA904CA7-68B8-4AE8-A78E-C99A43C65A88

P356

Q34552576-0B8778A3-A92F-4528-8ED6-1CC0A320898A

P407

Q34552576-B2E8EDCB-52E4-4834-A04B-015010211B39

P433

Q34552576-DF218F1F-5DE6-45FF-BD6D-79E825641766

P478

Q34552576-3A40AC38-E769-4EBC-9EAB-F20DB9C4FCDD

P50

Q34552576-AA247328-7A0D-482F-B565-3E45C9024D05

Q34552576-CEFF52CD-BD27-4097-AE00-6703C01C9BB7

Q34552576-E5B2A0C1-5C82-4ABF-B4AA-E556D8E24458

P577

Q34552576-3D76E42C-C48A-4185-8CD3-0E5D10AE276C

P698

Q34552576-75581A05-F7C3-47B9-82D6-A5B6C76A3D32

P356

JCO.2006.05.6762

P1433

Journal of Clinical Oncology

P1476

Phase II study of recombinant ...... dvanced neuroendocrine tumors.

@en

P2093

Alan P Venook

http://www.w3.org/2001/XMLSchema#string

Andrew X Zhu

http://www.w3.org/2001/XMLSchema#string

Ann Michelini

http://www.w3.org/2001/XMLSchema#string

Carolyn Sidor

http://www.w3.org/2001/XMLSchema#string

David P Ryan

http://www.w3.org/2001/XMLSchema#string

Emily K Bergsland

http://www.w3.org/2001/XMLSchema#string

Kate Kinsella

http://www.w3.org/2001/XMLSchema#string

Matthew H Kulke

http://www.w3.org/2001/XMLSchema#string

Peter C Enzinger

http://www.w3.org/2001/XMLSchema#string

Thomas J Lynch

http://www.w3.org/2001/XMLSchema#string

P304

3555-3561

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.05.6762

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Charles S. Fuchs

Jeffrey A Meyerhardt

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16877721

http://www.w3.org/2001/XMLSchema#string